Clario delivers the leading endpoint technology solutions for clinical trials. The company fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives.
Company Background
- Experience gained from over 26,000 clinical trials in more than 100 countries delivered in support of 870 regulatory approvals.
- Trusted partner to pharmaceutical and biotechnology companies.
- Unique combination of technology, scientific and therapeutic expertise with digital innovation and a strong focus on customer service.
Vision & Outlook
- Unlocking better evidence and transforming patients’ lives by driving further expansion of its operational capabilities.
- Continue to deliver best-in-class technology to enable richest clinical evidence.
- Boost diversity among patients in clinical trials, within its own inclusive workplace and among its suppliers.
Highlights & Updates
- Nordic Capitals re-invested alongside Astorg and Novo in 2020.
- Merger with Bioclinica created the company Clario in 2021.
- Recipient of the 2022 Top Workplaces award for D&I by Energage in 2022.
- In 2023, Clario submitted emissions reduction targets for validation by the Science-Bases Targets initiative (SBTi). Â
- In 2024, acquisition of AI-powered software company ArtiQ.
SECTOR
Healthcare
REVENUES 2023
EUR 1,040 million
EMPLOYEES
3,900
OWNERSHIP
Fund IX
INVESTMENT DATE
2020
HEAD OFFICE
Philadelphia, Pennsylvania, USA
